phthalazinol

 

Topic mentions per year

Topic mentions per year

1976-2005
012319762005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Experiments in monkeys have demonstrated that the chronic vasospasm and arterial injury reaction produced by subarachnoid blood… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1983
1983
Angiotensin (ANG) II-induced relaxations in isolated dog renal and cerebral arteries are postulated to be mediated by the release… (More)
Is this relevant?
1980
1980
In smooth muscle cells of the porcine coronary artery, phthalazinol (≦10−5 M) did not modify the membrane potential and the… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • table 1
Is this relevant?
1979
1979
Experiments in monkeys have demonstrated that the chronic vasospasm and arterial injury reaction produced by subarachnoid blood… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1979
1979
Phthalazinol (EG 626), a thromboxane A2 antagonist and cyclic AMP phosphodiesterase inhibitor, has been shown to prevent the… (More)
Is this relevant?
1978
1978
Using an in vitro system designed to measure arterial constriction, we have demonstrated the importance of platelet function in… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1978
1978
Atherosclerosis was produced in rabbits by feeding 1% cholesterol pellets for 15 weeks to 35 male rabbits divided into two equal… (More)
Is this relevant?
1977
1977
The inhibitor constants of several inhibitors for cyclic AMP- and cyclic GMP-phosphodiesterase from various organs are compared… (More)
Is this relevant?
1977
1977
Phthalazinol (EG-626), a newly synthesized cyclic AMP phosphodiesterase inhibitor, inhibited spontaneous phasic contractions (SPC… (More)
Is this relevant?
1976
1976
Three patients suffering from presenile dementia and two patients suffering from senile dementia were treated with phthalazinol… (More)
Is this relevant?